Glaxosmithkline Pharmaceuticals Ltd - Stock Valuation and Financial Performance

BSE: 500660 | NSE: GLAXO | Pharmaceuticals & Drugs | Mid Cap

Glaxosmithkline Phar Share Price

2,361.95 70.40 3.07%
as on 18-May'24 12:05

DeciZen - make an informed investing decision on Glaxosmithkline Phar

Overall Rating
Bole Toh

1. Quality

2. Valuation


3. Price Trend

Glaxosmithkline Pharmaceuticals stock performance -

mw4me loader
P/E Ratio (CD):
Market Cap:
38,820.2 Cr.
52-wk low:
52-wk high:

Is Glaxosmithkline Pharmaceuticals Ltd an attractive stock to invest in?

1. Is Glaxosmithkline Pharmaceuticals Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Glaxosmithkline Pharmaceuticals Ltd is a good quality company.

2. Is Glaxosmithkline Pharmaceuticals Ltd undervalued or overvalued?

The key valuation ratios of Glaxosmithkline Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Glaxosmithkline Pharmaceuticals Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Glaxosmithkline Pharmaceuticals Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

10 Year X-Ray of Glaxosmithkline Phar:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Glaxosmithkline Pharmaceuticals Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

ROCE % 23.1%26.8%18.7%14.5%16.9%20.4%10.8%26.4%17.5%26.7%-
Value Creation

Growth Parameters

Growth Parameters Colour Code Guide

Sales 2,6082,6902,8382,9082,8713,1283,2242,9263,2783,2523,454
Sales YoY Gr.-3.2%5.5%2.5%-1.3%8.9%3.1%-9.3%12.1%-0.8%-
Adj EPS 27.324.222.11820.325.212.425.521.434.634.8
YoY Gr.--11.3%-8.6%-18.8%13.3%24.1%-50.8%105.6%-16.3%62%-
BVPS (₹) 117.586.4128.9118.5121.4126.3107.587.3157.2102.993.6
Adj Net
Cash Flow from Ops. 281270139234473409491578811484-
Debt/CF from Ops. 0000000000-


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 2.5%2.5%0.3%-0.8%
Adj EPS 2.7%11.2%40.7%62%
Share Price 6.6% 13.2% 15.9% 84.6%

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on
Equity %
Op. Profit
Mgn %
Net Profit
Mgn %
Debt to
Working Cap
Cash Conv.

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 35.50%

Net Profit is growing at healthy rate in last 3 years 40.72%

Sales growth has been subdued in last 3 years 0.28%

Sales growth is not so good in last 4 quarters at 6.26%

Latest Financials - Glaxosmithkline Pharmaceuticals Ltd.

Standalone Consolidated
TTM EPS (₹) 34.5 34.8
TTM Sales (₹ Cr.) 3,407 3,454
BVPS (₹.) 94 93.6
Reserves (₹ Cr.) 1,424 1,416
P/BV 24.37 24.49
PE 66.39 65.80
From the Market
52 Week Low / High (₹) 1265.00 / 2649.95
All Time Low / High (₹) 20.31 / 2649.95
Market Cap (₹ Cr.) 38,820
Equity (₹ Cr.) 169.4
Face Value (₹) 10
Industry PE 47.9

Management X-Ray of Glaxosmithkline Phar:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Glaxosmithkline Phar

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
Operating Expenses 2,1242,7882,3602,4892,3662,5272,5672,3272,5162,447
Manufacturing Costs152398144136137143141137148129
Material Costs1,1721,3281,3251,3981,2411,3581,3081,2571,3561,285
Employee Cost 362493443483523537629616610595
Other Costs 439569447473464489489318402439
Operating Profit 483575478419506601657598762804
Operating Profit Margin (%) 18.5%17.1%16.9%14.4%17.6%19.2%20.4%20.4%23.2%24.7%
Other Income 22225912373551027911176101
Interest 0000016422
Depreciation 20252526384983796866
Exceptional Items 26-522461829-341-17312-1
Profit Before Tax 711756578511540683306454779836
Tax 230279202174189237213167398229
Profit After Tax 48247637633735144593287381608
PAT Margin (%) 18.5%14.2%13.3%11.6%12.2%14.2%2.9%9.8%11.6%18.7%
Adjusted EPS (₹)28.428.122.219.920.726.35.521.1100.036.1
Dividend Payout Ratio (%)88%111%113%75%85%76%727%142%90%89%

Balance Sheet

(All Figures are in Crores.)

Equity and Liabilities

Shareholders Fund 1,9901,8292,1832,0072,0572,1401,8211,4782,6631,743
Share Capital 8585858585169169169169169
Reserves 1,9051,7442,0991,9221,9731,9701,6511,3092,4941,574
Minority Interest0000000000
Long Term Debt4321100000
Short Term Debt0000000000
Trade Payables286308328279506406357466579428
Others Liabilities 7589933,9534,3015,0755,2588451,0671,2781,022
Total Liabilities 3,0373,1336,4656,5887,6397,8043,0233,0124,5203,193

Fixed Assets

Gross Block3433632282994065591,452601592650
Accumulated Depreciation243240244683129696215262321
Net Fixed Assets100123204253323430757386329329
CWIP 621152686059231,003120133120
Investments 100000000366518
Trade Receivables96100127171147120100216205192
Cash Equivalents 2,0421,9111,3929001,2961,1711,0831,1582,4851,156
Others Assets3805083,9494,2334,4494,593480692570517
Total Assets 3,0373,1336,4656,5887,6397,8043,0233,0124,5203,193

Cash Flow

(All Figures are in Crores.)
Cash Flow From Operating Activity 281338139234473409490578811484
PBT 6858085764655226546477232,476841
Adjustment -156-174-96-46-12-3113-26-1,636-40
Changes in Working Capital 11-37-124-27165-44446120-46
Tax Paid -244-252-206-161-202-194-180-147-112-262
Cash Flow From Investing Activity 189180499301-104-153-57418-406808
Capex -30-162-208-258-385-243-155-421,232-43
Net Investments 46163565472-3352092225-1,812956
Others 17317914287616706235175-105
Cash Flow From Financing Activity -494-497-638-511-307-358-428-696-524-1,543
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 0-1-1-1-100000
Interest Paid 00000-1-4-4-2-1
Dividend Paid -421-424-529-424-254-296-339-677-507-1,525
Others -72-72-108-86-52-61-85-15-16-17
Net Cash Flow -242102462-1026300-119-251
ROE (%)24.124.9518.7516.0817.2621.224.7117.4218.3927.58
ROCE (%)35.5439.5328.8124.3926.5632.5415.7627.7437.7238.06
Asset Turnover Ratio0.891.120.590.460.420.410.621.040.950.93
PAT to CFO Conversion(x)0.580.710.370.691.350.925.
Working Capital Days
Receivable Days14101518191612182120
Inventory Days43385858565853605551
Payable Days81828879115123106120141143

Glaxosmithkline Pharmaceuticals Ltd Stock News

Glaxosmithkline Pharmaceuticals Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Glaxosmithkline Phar on 18-May-2024 12:05 is ₹2,362.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 18-May-2024 12:05 the market cap of Glaxosmithkline Phar stood at ₹38,820.2.
The latest P/E ratio of Glaxosmithkline Phar as of 18-May-2024 12:05 is 66.39.
The latest P/B ratio of Glaxosmithkline Phar as of 18-May-2024 12:05 is 24.37.
The 52-week high of Glaxosmithkline Phar is ₹2,650 and the 52-week low is ₹1,265.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Glaxosmithkline Phar is ₹3,407 ( Cr.) .

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer.

With the combined heritage of Glaxo Wellcome plc and SmithKline Beecham plc, the company has played a pivotal role in the growth of the healthcare industry for almost a century. GSK has been a leader in India since inception, with a history replete with breakthrough innovations. Through the years, it has set benchmarks in conducting business responsibly, including the ways in which it research, develop, sell, and market its products.

The company is headquartered in Mumbai with various regional and sales hubs across the country. The company has made substantial investments in one large manufacturing facility in Nashik, in the state of Maharashtra.

Business area of the company

The company is engaged in research, manufacture and make available a broad range of medicines and vaccines that benefit people. The company’s Pharmaceuticals business has a broad portfolio of innovative and established medicines with commercial leadership in anti-infectives and dermatology. Its R&D approach focuses on science related to the immune system, use of genetics and advanced technologies. Meanwhile, Its Vaccines business has a broad portfolio and innovative pipeline of vaccines to protect people of all ages. The company is the leaders in India in the private segment.


  • Medicines
  • Vaccines
  • Prescribing Information
  • Child-resistant packaging

Award and recognition


  • Pharma & Medical Devices Summit & Excellence Awards 2017
  • GSK India wins the Gold Award at the TISS - CLO Summit
  • GSK India won the 'Gold award' in the Sales Enablement Category at the Tata Institute of Social Sciences (TISS) - CLO Summit in Mumbai.


  • GSK ranked among the 50 best companies in India as per People Capital Index (PCI). GSK was conferred this recognition at the HR Leadership Summit 2018.
  • GSK won the OPPI Salesforce Excellence Award 2018. The award recognises its efforts in launching and scaling an innovative, mobile based platform for sales readiness.
  • Tbact bags the Silver award for ‘Brand of the Year - Acute category 2018’ for marketing excellence. This award is a testimony to Teamwork and accountability displayed by each member of the cross functional team associated with Tbact.
  • The company has been recognised as one of the 100 Best Companies for Women by Working Mother and AVTAR. The award was received by members of the Women's Leadership Board.
  • GSK topped the Access to Medicine Index (ATMI) for the sixth time in a row. ATMI is an independent measure of the top 20 pharmaceutical companies’ efforts to improve access to healthcare in developing countries.
  • GSK's Corporate Communication and Government Affairs team was recognised by Reputation Today as the 30 Top Corporate Communication Teams in India.
  • The company has been recognised as one of the 100 Best Companies for Women by Working Mother and AVTAR for the second time in a row. This is an important milestone in its inclusion and diversity journey.
  • GSK has been recognised as the 'Best Workplaces for Women' by Great Places To Work in India. This award celebrates the efforts of the company's Women's Leadership Initiative towards creating an inclusive work environment.


  • GSK won the 2019 D&I in India Best Practices Awards in the 'Advancement of Women' category by Community Business.
  • GSK won the award for the 'Best Sales and Operations Planning Practice in Pharma' 2019.
  • T-Bact won 'Brand of the Year' award in the acute category for the second consecutive year in 2019 at the 6th AWACS Awards for marketing excellence.


  • GSK was recognised as India’s Best Workplaces for Women 2020 by Great Places to Work
  • GSK was recognised as 100 Best Companies for Women in India 2020 by Working Mother and AVTAR


  • 1924: Glaxo comes to India as H J Foster and Co.
  • 1947: Secondary manufacturing of pharmaceuticals begins at Glaxo’s Worli plant.
  • 1956: Primary production of vaccines begins at Worli plant.
  • 1968: Glaxo is registered as Limited company.
  • 1972: Scientists at Beecham Research laboratories discover Amoxycillin and launch Amoxil, which eventually becomes a widely used antibiotic.
  • 1981: Augmentin was launched by Beecham to combat a wide range of bacterial infections in children and adults and the antiviral Zovirax was launched by Wellcome for harpes infections.
  • 1983: Glaxo’s Nashik factory commissioned.
  • 1999: Glaxo India completes 75 years in India it is ranked ‘India’s most respective company’ by business world and again in 2003.
  • 2001: Legal merger of Glaxo India Limited and SmithKline Beecham Pharmaceuticals (India) Limited to form GlaxoSmithKline Pharmaceuticals Limited.
  • 2015: GSK acquired Novartis vaccines business (excluding influenza vaccines).
  • 2016: Launched Priorix- Tetra.
  • 2018: Launched Infanrix Hexa.
  • 2019: Launched Menveo (Quadrivalent Meningococcal Conjugate Vaccine).
  • 2019: The company has launched Spectrum, an employee resource group for raising awareness on LGBT+ among the employees.
  • 2019: Launched a development programme GSK WeLeAP - GSK Women Leadership Action Programme - to develop high potential mid-level women talent.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.